Sample of Cox's report, worth te suscription price
Facebook for Actually Smart People and the Killer Biotech App
So who is going to provide this blockbuster product, the useful interpretation of a person's genome? A related question for investors is who, if anyone, has enough competitive advantage to dominate the market.
For the last year or so, I've been talking about BioTime's LifeMap Sciences. Originally, BioTime set out to create the ultimate database of cell development -- from embryonic or induced pluripotent stem cells through the many thousands of paths they take to become all of the different cells in the human body. This database includes all the molecular genetic engineering knowledge about these different paths and how to influence them.
This database, which is online now, has allowed BioTime to partner with major suppliers of research products. Those products are linked in proximity to the cells that researchers are interested in.
Then, BioTime acquired exclusive rights to GeneCards and MalaCards, developed and maintained by Israel's prestigious Weizmann Institute of Science. Israel, incidentally, is the world center of bioinformatic research and progress. Together, these three projects compose the only integrated database of constantly updated information on the specific cell types, the genes functioning within those cells and genetic information about the diseases that afflict them.
This is the most important biological database in history, and yesterday's press release from BioTime provides some of the evidence that this is so. Essentially, they have disclosed that this combined database, with deep-linked products for sale, has about 2 million regular unique visitors per month. These users are, for the most part, scientists, with a few exceptions like me. Many of these users, therefore, control significant research budgets.
For purposes of valuation, companies like LinkedIn and Facebook estimate that each unique regular visitor is worth about $65. LifeMap's users are, obviously, more valuable. Moreover, research suppliers and pharmaceutical companies actually pay for access to the database. But let's assume that these highly educated and connected users are worth only $100 per unique set of eyeballs. That's $200 million -- so far.
DISCLOSURE: I don't know Cox, we have neverr spoken or corresponded. We have no relationship other than my subscription which I bought for BTX and STSI.